FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134787029> ?p ?o ?g. }

• W2134787029 endingPage "1019" @default.
• W2134787029 startingPage "1011" @default.
• W2134787029 abstract "ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study.In this phase 1 study, patients with ALK-positive stage III or IV NSCLC received oral crizotinib 250 mg twice daily in 28-day cycles. Endpoints included tumour responses, duration of response, time to tumour response, progression-free survival (PFS), overall survival at 6 and 12 months, and determination of the safety and tolerability and characterisation of the plasma pharmacokinetic profile of crizotinib after oral administration. Responses were analysed in evaluable patients and PFS and safety were analysed in all patients. This study is registered with ClinicalTrials.gov, number NCT00585195.Between Aug 27, 2008, and June 1, 2011, 149 ALK-positive patients were enrolled, 143 of whom were included in the response-evaluable population. 87 of 143 patients had an objective response (60·8%, 95% CI 52·3-68·9), including three complete responses and 84 partial responses. Median time to first documented objective response was 7·9 weeks (range 2·1-39·6) and median duration of response was 49·1 weeks (95% CI 39·3-75·4). The response rate seemed to be largely independent of age, sex, performance status, or line of treatment. Median PFS was 9·7 months (95% CI 7·7-12·8). Median overall survival data are not yet mature, but estimated overall survival at 6 and 12 months was 87·9% (95% CI 81·3-92·3) and 74·8% (66·4-81·5), respectively. 39 patients continued to receive crizotinib for more than 2 weeks after progression because of perceived ongoing clinical benefit from the drug (12 for at least 6 months from the time of their initial investigator-defined disease progression). Overall, 144 (97%) of 149 patients experienced treatment-related adverse events, which were mostly grade 1 or 2. The most common adverse events were visual effects, nausea, diarrhoea, constipation, vomiting, and peripheral oedema. The most common treatment-related grade 3 or 4 adverse events were neutropenia (n=9), raised alanine aminotransferase (n=6), hypophosphataemia (n=6), and lymphopenia (n=6).Crizotinib is well tolerated with rapid, durable responses in patients with ALK-positive NSCLC. There seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed." @default.
• W2134787029 created "2016-06-24" @default.
• W2134787029 creator A5003826371 @default.
• W2134787029 creator A5017123525 @default.
• W2134787029 creator A5019037704 @default.
• W2134787029 creator A5020504047 @default.
• W2134787029 creator A5024045160 @default.
• W2134787029 creator A5035532245 @default.
• W2134787029 creator A5040093136 @default.
• W2134787029 creator A5041640815 @default.
• W2134787029 creator A5045419282 @default.
• W2134787029 creator A5045959942 @default.
• W2134787029 creator A5048675362 @default.
• W2134787029 creator A5053711811 @default.
• W2134787029 creator A5056275493 @default.
• W2134787029 creator A5060033755 @default.
• W2134787029 creator A5061648315 @default.
• W2134787029 creator A5064953304 @default.
• W2134787029 creator A5069077526 @default.
• W2134787029 creator A5075625649 @default.
• W2134787029 creator A5078338048 @default.
• W2134787029 creator A5080311196 @default.
• W2134787029 creator A5080462237 @default.
• W2134787029 creator A5082517668 @default.
• W2134787029 creator A5088474933 @default.
• W2134787029 creator A5088637763 @default.
• W2134787029 date "2012-10-01" @default.
• W2134787029 modified "2023-10-17" @default.
• W2134787029 title "Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study" @default.
• W2134787029 cites W1712727770 @default.
• W2134787029 cites W1730923580 @default.
• W2134787029 cites W1969914656 @default.
• W2134787029 cites W1981712321 @default.
• W2134787029 cites W1997476230 @default.
• W2134787029 cites W1998371249 @default.
• W2134787029 cites W2015436643 @default.
• W2134787029 cites W2019539885 @default.
• W2134787029 cites W2031159738 @default.
• W2134787029 cites W2031494655 @default.
• W2134787029 cites W2037139573 @default.
• W2134787029 cites W2038056960 @default.
• W2134787029 cites W2050368996 @default.
• W2134787029 cites W2055402151 @default.
• W2134787029 cites W2077582166 @default.
• W2134787029 cites W2080903186 @default.
• W2134787029 cites W2081095165 @default.
• W2134787029 cites W2095618958 @default.
• W2134787029 cites W2096156234 @default.
• W2134787029 cites W2104830962 @default.
• W2134787029 cites W2113327188 @default.
• W2134787029 cites W2114032749 @default.
• W2134787029 cites W2123727052 @default.
• W2134787029 cites W2128208856 @default.
• W2134787029 cites W2135329354 @default.
• W2134787029 cites W2139110945 @default.
• W2134787029 cites W2139248078 @default.
• W2134787029 cites W2139939379 @default.
• W2134787029 cites W2140333474 @default.
• W2134787029 cites W2140334822 @default.
• W2134787029 cites W2147038864 @default.
• W2134787029 cites W2147689725 @default.
• W2134787029 cites W2150424194 @default.
• W2134787029 cites W2161650275 @default.
• W2134787029 cites W2168691181 @default.
• W2134787029 cites W2170874935 @default.
• W2134787029 cites W2172208023 @default.
• W2134787029 doi "https://doi.org/10.1016/s1470-2045(12)70344-3" @default.
• W2134787029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3936578" @default.
• W2134787029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22954507" @default.
• W2134787029 hasPublicationYear "2012" @default.
• W2134787029 type Work @default.
• W2134787029 sameAs 2134787029 @default.
• W2134787029 citedByCount "1131" @default.
• W2134787029 countsByYear W21347870292012 @default.
• W2134787029 countsByYear W21347870292013 @default.
• W2134787029 countsByYear W21347870292014 @default.
• W2134787029 countsByYear W21347870292015 @default.
• W2134787029 countsByYear W21347870292016 @default.
• W2134787029 countsByYear W21347870292017 @default.
• W2134787029 countsByYear W21347870292018 @default.
• W2134787029 countsByYear W21347870292019 @default.
• W2134787029 countsByYear W21347870292020 @default.
• W2134787029 countsByYear W21347870292021 @default.
• W2134787029 countsByYear W21347870292022 @default.
• W2134787029 countsByYear W21347870292023 @default.
• W2134787029 crossrefType "journal-article" @default.
• W2134787029 hasAuthorship W2134787029A5003826371 @default.
• W2134787029 hasAuthorship W2134787029A5017123525 @default.
• W2134787029 hasAuthorship W2134787029A5019037704 @default.
• W2134787029 hasAuthorship W2134787029A5020504047 @default.
• W2134787029 hasAuthorship W2134787029A5024045160 @default.
• W2134787029 hasAuthorship W2134787029A5035532245 @default.
• W2134787029 hasAuthorship W2134787029A5040093136 @default.
• W2134787029 hasAuthorship W2134787029A5041640815 @default.
• W2134787029 hasAuthorship W2134787029A5045419282 @default.
• W2134787029 hasAuthorship W2134787029A5045959942 @default.
• W2134787029 hasAuthorship W2134787029A5048675362 @default.
• W2134787029 hasAuthorship W2134787029A5053711811 @default.

• next